Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma

Olga Wysocka; Julita Kulbacka; Jolanta Saczko

doi:10.5114/pg.2016.61438

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2016
vol. 11

Send email

Copy url:

abstract:

Review paper

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma

Olga Wysocka

,

Julita Kulbacka

,

Jolanta Saczko

Gastroenterology Rev 2016; 11 (3): 155–162

DOI: https://doi.org/10.5114/pg.2016.61438

Online publish date: 2016/07/22

View full text Get citation

PlumX metrics:

Pancreatic cancer is one of the most aggressive and deadly malignancies. Despite better understanding of its biology and pathogenesis, contemporary treatment regimens are still insufficient. Along with the introduction of new treatment agents and combination therapy, the response rates are increasing, but these scores do not go with overall survival, and results are frequently conflicting. Therefore, contemporary medicine faces the challenge of expanding the knowledge base and practice on all grounds – pathology, factor risk, diagnosis, and finally surgical and palliative treatment of this disease. This paper provides a review of current adjuvant and neoadjuvant regimens and the role of experimental therapies in pancreatic ductal adenocarcinoma.

keywords:

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma

Olga Wysocka , Julita Kulbacka , Jolanta Saczko

pancreatic cancer, epidemiology, treatment

Olga Wysocka

,

Julita Kulbacka

,

Jolanta Saczko